Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis

Journal of Crohn's and Colitis

Volumn 10, Issue 4, 2016, Pages 484-494

  Komaki, Yuga ^a   Komaki, Fukiko ^a   Ido, Akio ^b   Sakurabaa, Atsushi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Immunosuppressant; Meta analysis; Systematic review; Tacrolimus; Ulcerative colitis

Indexed keywords

PLACEBO; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADVERSE OUTCOME; ARTICLE; COLON RESECTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COLITIS, ULCERATIVE;

COLITIS, ULCERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84966393464     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv221     Document Type: Article

References (46)

1. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 2006;41:10-6.
2. Sakuraba A, Sato T, Kamada N, et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 2009;137:1736-45.
3. Sakuraba A, Sato T, Matsukawa H, et al. The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study. Int J Colorectal Dis 2012;27:947-52.
4. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-7.
5. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a metaregression. Clin Gastroenterol Hepatol 2007;5:103-10.
6. Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the longterm prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol 2010;45:1129-37.
7. Katz JA. Medical and surgical management of severe colitis. Semin Gastrointest Dis 2000;11:18-32.
8. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus [FK506]. Am J Gastroenterol 1998;93:1860-6.
9. Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 2011;46:129-37.
10. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus [FK506] therapy in refractory ulcerative colitis. Gut 2006;55:1255-62.
11. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus [FK506] in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012;18:803-8.
12. Stenke E, Hussey S. Ulcerative colitis: management in adults, children and young people [NICE Clinical Guideline CG166]. Arch Dis Child Pract Ed 2014;99:194-7.
13. Matsuoka K, Hibi T. Treatment guidelines in inflammatory bowel disease: the Japanese perspectives. Dig Dis 2013;31:363-7.
14. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841- 5.
15. Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorect Dis 2013;28:287-93.
16. The U. S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus [FK 506] and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
19. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
20. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
21. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus [FK 506] on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:415-23.
22. Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007;45:306-11.
23. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589-97.
24. Benson A, Barrett T, Sparberg M, et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008;14:7-12.
25. Murano M, Narabayashi K, Nouda S, et al. The Safety and Efficacy of Rapid Induction Therapy of Tacrolimus With Severe Ulcerative Colitis Refractory to Steroid Therapy. Gastrointest Endosc 2011;73:AB442.
26. Inoue T, Murano M, Narabayashi K, et al. The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy. Intern Med 2013;52:15-20.
27. Hiraoka S, Kato J, Inokuchi T, et al. Prediction of Dose of Tacrolimus Required for Remission Induction of Ulcerative Colitis Patients. BMC Gastroenterol 2015;15:53.
28. Matsuura M, Nakase H, Yoshino T, et al. Long-term follow-up in patients with ulcerative colitis treated with tacrolimus: early and longterm data from a retrospective observational study. J Crohns Colitis 2013;7:S190.
29. Miyoshi J, Matsuoka K, Inoue N, et al. Mucosal healing with oral tacrolimus is associated with favourable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis 2013;7:e609-14.
30. Boschetti G, Nancey S, Moussata D, et al. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderateto- severe ulcerative colitis refractory to prior treatment. Dig Liver Dis 2014;46:875-80.
31. Ikeya K, Sugimoto K, Kawasaki S, et al. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict longterm prognosis. Dig Liver Dis 2015;47:365-71.
32. Minami N, Yoshino T, Matsuura M, et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol 2015;2:e000021.
33. Kawakami K, Inoue T, Murano M, et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015;21:1880-6.
34. Nakamura M, Hida N, Iimuro M, et al. Incidence and Severity of Acute Kidney Injury During Oral Tacrolimus Treatment in Patients With Refractory Ulcerative Colitis. Gastroenterology 2015;148:S-237.
35. Watanabe O, Nakamura M, Yamamura T, et al. The Efficacy of Tacrolimus and the Usefulness of Endoscopy in Predicting Its Efficacy in Patients With Refractory Ulcerative Colitis. Gastrointest Endosc 2015;81:AB240.
36. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 2006;101:1048-56.
37. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:129-34.
38. Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Ther 2013;37:129-36.
39. Landy J, Wahed M, Peake ST, et al. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres. J Crohns Colitis 2013;7:e516-21.
40. Navas-Lopez VM, Blasco Alonso J, Serrano Nieto MJ, et al. Oral tacrolimus for paediatric steroid-resistant ulcerative colitis. J Crohns Colitis 2014;8:64-9.
41. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus [FK506]. Inflamm Bowel Dis 2002;8:317-24.
42. Kimura K, Matsuoka K, Miyoshi J, et al. The switching therapy between infliximab and tacrolimus in steroid-refractory ulcerative colitis. J Crohns Colitis 2013;7:S144-5.
43. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909- 15.
44. Kur F, Reichenspurner H, Meiser B, et al. Tacrolimus [FK506] as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 1999;47:174-8.
45. Margreiter R; Group ETvCMRTS. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359:741-6.
46. Kong Y, Wang D, Shang Y, et al. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PloS One 2011;6:e24387.